137 related articles for article (PubMed ID: 19462720)
1. [Positron emission tomography (PET) and PET-CT in renal, bladder and prostate cancer: update].
Delgado Bolton RC; Mucientes Rasilla J; Pérez Castejón MJ; Carreras Delgado JL
Actas Urol Esp; 2009 Jan; 33(1):11-23. PubMed ID: 19462720
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
[TBL] [Abstract][Full Text] [Related]
4. FDG in Urologic Malignancies.
Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
[TBL] [Abstract][Full Text] [Related]
5. Imaging in genitourinary cancer from the urologists' perspective.
Tsakiris P; de la Rosette J
Cancer Imaging; 2007 May; 7(1):84-92. PubMed ID: 17535776
[TBL] [Abstract][Full Text] [Related]
6. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
9. The diagnosis, staging, and follow-up of carcinomas of the kidney, bladder, and prostate: the role of cross-sectional imaging.
Singer J; McClennan BL
Semin Ultrasound CT MR; 1989 Dec; 10(6):481-97. PubMed ID: 2697358
[No Abstract] [Full Text] [Related]
10. Diuretic 18F-Fluorodeoxyglucose PET/Computed Tomography in Evaluation of Genitourinary Malignancies.
Agarwal KK; Roy SG; Kumar R
PET Clin; 2016 Jan; 11(1):39-46. PubMed ID: 26590442
[TBL] [Abstract][Full Text] [Related]
11. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
12. Possible role of FDG-PET in the evaluation of urologic malignancies.
Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous laparoscopic management of 3 urological malignancies.
Deng DY; Meng MV; Grossfeld GD; Stoller ML
J Urol; 2002 May; 167(5):2125-6. PubMed ID: 11956456
[No Abstract] [Full Text] [Related]
14. 18F-FDG PET/CT evaluation of lymphoma with renal involvement: comparison with renal carcinoma.
Ye XH; Chen LH; Wu HB; Feng J; Zhou WL; Yang RM; Bu ZB; Ding Y; Guan J; Wang QS
South Med J; 2010 Jul; 103(7):642-9. PubMed ID: 20531045
[TBL] [Abstract][Full Text] [Related]
15. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
16. Imaging following cryoablation of a renal lesion.
Wagner AA; Solomon SB; Kavoussi LR
Nat Clin Pract Urol; 2005 Jan; 2(1):52-7; quiz 58. PubMed ID: 16474577
[TBL] [Abstract][Full Text] [Related]
17. Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24].
See WA
Urol Oncol; 2014 Nov; 32(8):1350. PubMed ID: 25488385
[TBL] [Abstract][Full Text] [Related]
18. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
20. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.
Ren J; Yuan L; Wen G; Yang J
Acta Radiol; 2016 Apr; 57(4):487-93. PubMed ID: 25907118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
